Abstract:The CYP2A6 gene spans a region of approximately 6 kb pairs consisting of 9 exons and has been mapped to the long arm of chromosome 19 (between 19q12 and 19q13.2). The CYP2A6 protein has 494 amino acids and is an important hepatic Phase I enzyme that metabolizes approximately 3% of therapeutic drugs (n > 30; e.g. valproic acid, pilocarpine, tegafur, fadrozole, ifosfamide, cyclophosphamide, nicotine, tamoxifen, promazine, propofol, and cisapride), environmental toxicants (e.g. gasoline additives), and many procarcinogens such as nitrosamines and aflatoxin B(1). This enzyme also participates in the biotransformation of several endogenous compounds such as retinoid acids and steroids. Because CYP2A6 is responsible for 70-80% of the initial metabolism of nicotine, CYP2A6 has been proposed to be a novel target for smoking cessation. Site-directed mutagenesis and homology modeling studies have identified a number of amino acids (e.g. F300, A301, S208, S369, and L370) that play a role in substrate recognition and binding. CYP2A6 shows a crystal structure with a compact, hydrophobic active site with Asn297 serving as one hydrogen bond donor and orienting substrates for regio-selective oxidation. CYP2A6 contains the second smallest active site cavity among the human CYPs with known structures. The regulation mechanism of CYP2A6 expression is not fully understood, but available data suggest that several nuclear receptors including constitutive androstane receptor, pregnane X receptor and glucocorticoid receptor are involved in its regulation. Pilocarpine and tranylcypromine are commonly used as selective competitive inhibitors of CYP2A6. Selegiline, methoxsalen, (R)-(+) menthofuran and decursinol angelate are mechanism-based inhibitors of CYP2A6. Both in vitro and in vivo studies have demonstrated a wide (20- to >100-fold) interindividual variation in CYP2A6 expression and activity, which is due primarily to genetic polymorphisms in the CYP2A6 gene, but CYP2A6 activity is also modified by certain drugs and pathological and environmental factors. To date, more than 36 variant alleles (*1B through *37) of the CYP2A6 gene have been identified. There have been 278 SNPs found in the CYP2A6 upstream sequence, 8 introns and 9 exons in NCBI dbSNP. Polymorphism of CYP2A6 has been associated with smoking behavior, drug clearance and lung cancer risk. Further studies are warranted to explore the role of CYP2A6 in clinical practice, drug development and toxicology.

Identification of variable amino acids in the SRS1 region of CYP6B1 modulating furanocoumarin metabolism.

Molecular Docking Of Substrates And Inhibitors In The Catalytic Site Of Cyp6b1, An Insect Cytochrome P450 Monooxygenase

Metabolism of Linear and Angular Furanocoumarins by Papilio Polyxenes Cyp6b1 Co-Expressed with Nadph Cytochrome P450 Reductase

Coumarin Derivatives as Substrate Probes of Mammalian Cytochromes P450 2B4 and 2B6: Assessing the Importance of 7-Alkoxy Chain Length, Halogen Substitution, and Non-Active Site Mutations

Single Amino Acid Variations Drive Functional Divergence of Cytochrome P450s in Helicoverpa Species

Mutagenesis and Molecular Dynamics Suggest Structural and Functional Roles for Residues in the N-terminal Portion of the Cytochrome P450 2B1 I Helix

Roles of the Variable P450 Substrate Recognition Sites SRS1 and SRS6 in Esfenvalerate Metabolism by CYP6AE Subfamily Enzymes in Helicoverpa Armigera

Identification of the N-terminal residues responsible for the differential microdomain localization of CYP1A1 and CYP1A2

Identification of New Substrates and Inhibitors of Human CYP2A7

Functional Characterization and Mechanistic Modeling of the Human Cytochrome P450 Enzyme CYP4A22

Structure, Function, Regulation and Polymorphism of Human Cytochrome P450 2A6

Identification and in vivo functional analysis of furanocoumarin-responsive cytochrome P450s in a Rutaceae-feeding Papilio butterfly

A Theoretical Study on the Mechanism of a Superficial Mutation Inhibiting the Enzymatic Activity of CYP1A2

The critical role of porcine cytochrome P450 3A46 in the bioactivation of aflatoxin B1

Structure-function analysis of porcine cytochrome P450 3A29 in the hydroxylation of T-2 toxin as revealed by docking and mutagenesis studies.

MD simulations and QM/MM calculations show that single-site mutations of cytochrome P450 BM3 alter the active site's complexity and the chemoselectivity of oxidation without changing the active species.

Structural basis for the mutation-induced dysfunction of human CYP2J2: a computational study.

Structural Basis for the Properties of Two Single-Site Proline Mutants of Cyp102a1 (P450(bm3))

Reduced Catalytic Activity of P450 2A6 Mutants with Coumarin: A Computational Investigation

Using lineage-specific patterns to understand convergence of enzymatic functions led to the identification of Moraceae-specific P450s involved in furanocoumarin biosynthesis

Identification And Functional Assessment Of A New Cyp2c9 Allelic Variant Cyp2c9(Star)59